TP 20

Drug Profile

TP 20

Alternative Names: sCR1sLex

Latest Information Update: 05 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer Celldex Therapeutics Inc
  • Class Anti-ischaemics
  • Mechanism of Action Complement system protein inhibitors; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Reperfusion injury; Stroke

Most Recent Events

  • 17 Jul 2003 This compound is still in active development for stroke
  • 17 Jul 2003 No development reported - Preclinical for Reperfusion injury in USA (IV)
  • 17 Jun 2002 This compound is still in active development for myocardial infarction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top